Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

Background: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Oshima, S. Washino, S. Shirotake, H. Takeshita, M. Inoue, Y. Miura, A. Nakayama, S. Nagamoto, T. Nakayama, K. Izumi, M. Oyama, S. Kawakami, K. Saito, Y. Matsuoka, T. Miyagawa
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
neutrophil to lymphocyte ratio
tumour burden
renal cell carcinoma
nivolumab
ipilimumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000845
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items